QLT Inc. (USA)  

(Public, NASDAQ:QLTI)   Watch this stock  
Find more results for QLTI
5.95
+0.05 (0.85%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.89 - 6.01
52 week 3.69 - 8.61
Open 5.95
Vol / Avg. 0.00/66,329.00
Mkt cap 303.94M
P/E     -
Div/yield 3.92
EPS -0.55
Shares 51.08M
Beta 0.87
Inst. own 51%
Apr 28, 2014
Q1 2014 QLT Inc. Earnings Release (Estimated) Add to calendar
Feb 28, 2014
Q4 2013 QLT Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -17.35% -11.33%
Return on average equity -18.11% -11.78%
Employees 59 -
CDP Score - -

Address

Suite 250, 887 Great Northern Way
VANCOUVER, BC V5T 4T5
Canada
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. It develops QLT091001, a synthetic retinoid compound for the potential treatment of certain inherited retinal degenerative diseases. In September 2012,it sold all of its assets related to Visudyne to Valeant Pharmaceuticals International, Inc. (Valeant). It also sold Qcellus laser and certain other photodynamic therapy intellectual property, In April 2013, it sold its punctal plug drug delivery system (PPDS) technology (Technology) to Mati Therapeutics Inc. (Mati). It is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. It is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 44
Bio & Compensation  - Reuters
Sukhi Jagpal Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Alexander R. Lussow Ph.D. Senior Vice President - Business Development & Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
John W. Kozarich Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey A. Meckler Independent Director
Age: 46
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
John C. Thomas Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters